

AltÃ©s, Albert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9362586/publications.pdf>

Version: 2024-02-01

76
papers

3,148
citations

196777

29
h-index

175968

55
g-index

86
all docs

86
docs citations

86
times ranked

3916
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of a self-management programme in the treatment of antivitamin K oral anticoagulants. A feasibility study. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 388-393.	0.1	0
2	Eficacia de un programa de autocontrol en el tratamiento con anticoagulantes orales antivitamina K. Estudio de factibilidad. <i>Medicina Clínica</i> , 2020, 154, 388-393.	0.3	0
3	Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients. <i>Angiogenesis</i> , 2019, 22, 433-440.	3.7	28
4	Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. <i>Hepatology International</i> , 2018, 12, 83-86.	1.9	41
5	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Åyears follow-up of a phase 2 trial. <i>Annals of Hematology</i> , 2017, 96, 639-646.	0.8	7
6	Hereditary hemochromatosis. Problems in diagnosis and treatment. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 424-428.	0.1	0
7	Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?. <i>Pharmacogenomics</i> , 2014, 15, 1079-1090.	0.6	42
8	Pharmacogenetic analysis in the treatment of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1706-1712.	0.6	5
9	Efficacy and Safety Of Tamsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience. <i>Blood</i> , 2013, 122, 5117-5117.	0.6	1
10	Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. <i>Pharmacogenomics Journal</i> , 2012, 12, 379-385.	0.9	42
11	Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1681-1689.	1.2	23
12	Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 33-38.	1.1	76
13	Detection of hereditary hemochromatosis and biochemical iron overload in primary care: A multicenter case finding study in Spain. <i>American Journal of Hematology</i> , 2010, 85, 294-296.	2.0	6
14	Does the SLC40A1 gene modify HFE-related haemochromatosis phenotypes?. <i>Annals of Hematology</i> , 2009, 88, 341-345.	0.8	16
15	Mutations in HAMP and HJV genes and their impact on expression of clinical hemochromatosis in a cohort of 100 Spanish patients homozygous for the C282Y mutation of HFE gene. <i>Annals of Hematology</i> , 2009, 88, 951-955.	0.8	16
16	Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. <i>British Journal of Cancer</i> , 2008, 99, 1050-1055.	2.9	107
17	Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes. <i>Clinical Cancer Research</i> , 2008, 14, 1788-1796.	3.2	72
18	Methylenetetrahydrofolate Reductase Gene Polymorphisms: Genomic Predictors of Clinical Response to Fluoropyrimidine-Based Chemotherapy in Females. <i>Journal of Clinical Oncology</i> , 2008, 26, 3468-3468.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. <i>Clinical Cancer Research</i> , 2008, 14, 155-161.	3.2	117
20	Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?. <i>Pharmacogenomics Journal</i> , 2008, 8, 315-320.	0.9	11
21	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , 2008, 93, 207-214.	1.7	24
22	Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy. <i>Anti-Cancer Drugs</i> , 2007, 18, 821-825.	0.7	12
23	Early clinical impact of iron overload in stem cell transplantation. A prospective study. <i>Annals of Hematology</i> , 2007, 86, 443-447.	0.8	58
24	The relationship between iron overload and clinical characteristics in a Spanish cohort of 100 C282Y homozygous hemochromatosis patients. <i>Annals of Hematology</i> , 2007, 86, 831-835.	0.8	11
25	Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 41-45.	0.6	23
26	Genotyping the HFE gene by melting point analysis with the LightCycler system: Pros and cons. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 288-291.	0.6	9
27	Genotype-phenotype correlation in a Spanish population homozygous for the H63D mutation of the HFE gene. <i>Annals of Hematology</i> , 2006, 85, 340-342.	0.8	23
28	Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 835-840.	1.1	75
29	The relationship between transferrin saturation and erythropoiesis during stem cell transplantation. <i>Haematologica</i> , 2006, 91, 992-3.	1.7	3
30	Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. <i>European Journal of Haematology</i> , 2005, 74, 144-151.	1.1	68
31	Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. <i>Annals of Oncology</i> , 2005, 16, 1508-1513.	0.6	46
32	Prevalence of the C282Y, H63D, and S65C Mutations of the HFE Gene in 1,146 Newborns from a Region of Northern Spain. <i>Genetic Testing and Molecular Biomarkers</i> , 2004, 8, 407-410.	1.7	33
33	Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. <i>Annals of Oncology</i> , 2004, 15, 1484-1489.	0.6	66
34	Measurement of liver iron overload by magnetic induction using a planar gradiometer: preliminary human results. <i>Physiological Measurement</i> , 2004, 25, 315-323.	1.2	32
35	Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). <i>Histopathology</i> , 2004, 45, 268-274.	1.6	37
36	Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. <i>Bone Marrow Transplantation</i> , 2004, 34, 505-509.	1.3	116

#	ARTICLE	IF	CITATIONS
37	UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2004, 91, 678-682.	2.9	296
38	Single nucleotide polymorphism in the 5â€² tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. <i>International Journal of Cancer</i> , 2004, 112, 733-737.	2.3	118
39	Patients with biochemical iron overload: causes and characteristics of a cohort of 150 cases. <i>Annals of Hematology</i> , 2003, 82, 127-130.	0.8	46
40	Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. <i>Experimental Hematology</i> , 2003, 31, 1039-1043.	0.2	21
41	Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. <i>British Journal of Haematology</i> , 2003, 122, 394-403.	1.2	292
42	Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure. <i>Bone Marrow Transplantation</i> , 2003, 32, 869-872.	1.3	18
43	Phase I/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the Spanish experience. <i>Transplantation Proceedings</i> , 2003, 35, 742-743.	0.3	5
44	Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Blood</i> , 2003, 102, 1108-1113.	0.6	100
45	Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 29, 987-989.	1.3	111
46	CD34+-enrichedâ€”CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders. <i>Experimental Hematology</i> , 2002, 30, 824-830.	0.2	23
47	Prognostic factors influencing feasibility of cytogenetic and molecular analysis in leukapheresis products in chronic myelogenous leukemia patients. <i>Annals of Hematology</i> , 2002, 81, 710-716.	0.8	1
48	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 976-984.	1.2	163
49	Autologous Stem-Cell Transplantation for Hodgkinâ€™s Disease: Results and Prognostic Factors in 494 Patients From the Grupo EspaÃ±ol de Linfomas/Transplante AutÃ³logo de MÃ©dula Ã“sea Spanish Cooperative Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 1395-1404.	0.8	225
50	Predictive factors for a successful mobilization of peripheral blood CD34 + cells in multiple myeloma. <i>Annals of Hematology</i> , 2001, 80, 592-597.	0.8	78
51	Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2001, 23, 505.	0.8	9
52	Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders. <i>Bone Marrow Transplantation</i> , 2000, 26, 127-132.	1.3	6
53	Bacteremia by Gram-Negative Bacilli in Patients with Hematologic Malignancies. <i>Acta Haematologica</i> , 1999, 102, 7-11.	0.7	18
54	Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 283-287.	1.3	57

#	ARTICLE	IF	CITATIONS
55	Enhanced myeloid specificity of CD 117 compared with CD13 and CD33. <i>Leukemia Research</i> , 1999, 23, 341-347.	0.4	30
56	Lack of association between venous thrombosis and subsequent malignancy in a retrospective cohort study in young patients. , 1999, 60, 181-184.		10
57	Lack of association between venous thrombosis and subsequent malignancy in a retrospective cohort study in young patients. , 1999, 60, 181.		1
58	Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 1998, 21, 1023-1027.	1.3	15
59	Short-course thrombolysis as the first line of therapy for cardiac valve thrombosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1998, 115, 780-784.	0.4	42
60	Effect of Discontinuing Prophylaxis with Norfloxacin in Patients with Hematologic Malignancies and Severe Neutropenia. <i>Acta Haematologica</i> , 1998, 99, 206-211.	0.7	38
61	Activated protein C resistance assay when applied in the general population. <i>American Journal of Obstetrics and Gynecology</i> , 1997, 176, 358-359.	0.7	13
62	Vitamin E serum levels in patients with leukemia, lymphoma and myeloma. <i>European Journal of Epidemiology</i> , 1997, 13, 853-854.	2.5	2
63	Late hemorrhagic disease of the newborn as a cause of intracerebral bleeding. <i>Annals of Hematology</i> , 1997, 75, 65-66.	0.8	14
64	Pentosan polysulfate-induced thrombocytopenia: a case diagnosed with an ELISA test used for heparin-induced thrombocytopenia. <i>Annals of Hematology</i> , 1996, 73, 51-52.	0.8	7
65	Hematopoietic growth factor (G-CSF or GM-CSF) after salvage chemotherapy in refractory or relapsed adult de novo acute leukemia. <i>Leukemia and Lymphoma</i> , 1996, 20, 321-326.	0.6	3
66	Hereditary Macrothrombocytopenia and Pregnancy. <i>Thrombosis and Haemostasis</i> , 1996, 76, 029-033.	1.8	3
67	Hemostatic Disturbances in Acute Ischemic Stroke: A Study of 86 Patients. <i>Acta Haematologica</i> , 1995, 94, 10-15.	0.7	39
68	Heparin-induced thrombocytopenia and heart operation: Management with tedelparin. <i>Annals of Thoracic Surgery</i> , 1995, 59, 508-509.	0.7	26
69	Reply. <i>Annals of Thoracic Surgery</i> , 1995, 60, 1160-1161.	0.7	1
70	<i>Capnocytophaga</i> Bacteremia in Neutropenic Patients: Report of Two Cases. <i>Acta Haematologica</i> , 1994, 92, 46-47.	0.7	2
71	Prevention of invasive fungal infections during bone marrow transplantation. <i>Annals of Hematology</i> , 1994, 69, 157-157.	0.8	1
72	Spontaneous splenic rupture as the initial manifestation of acute lymphoblastic leukaemia: Immunophenotype and cytogenetics. <i>Annals of Hematology</i> , 1994, 68, 143-144.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation. American Journal of Hematology, 1994, 46, 60-61.	2.0	1
74	Reduced Transfusion Requirements in a Splenectomized Patient Undergoing Bone Marrow Transplantation. Acta Haematologica, 1994, 92, 167-168.	0.7	6
75	Infection by <i>Listeria monocytogenes</i> in the early period post bone marrow transplantation. European Journal of Haematology, 1994, 53, 251-252.	1.1	3
76	Treatment of Refractory and Relapsed Adult Acute Leukemia Using a Uniform Chemotherapy Protocol. Leukemia and Lymphoma, 1993, 11, 393-398.	0.6	7